Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $58.36 -0.82%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
ORPB, PBCO, SICP, More
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
- Oregon Pacific Bancorp (ORPB) Tops Q3 EPS by 38c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
